Psychopharmacology and Psychiatry Updates

In this episode, we explore pramipexole—a Parkinson's medication—as a promising add-on treatment for treatment-resistant bipolar depression. Could a dopamine agonist be the unexpected solution when standard mood stabilizers and antipsychotics fail? We examine the PAX-BD trial's findings, safety concerns, and practical clinical applications.
Faculty: Kristin Raj, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.5 CME: Quick Take Vol. 78
Treatment-Resistant Bipolar Depression: Is Adjunctive Pramipexole An Option?

In this episode, we explore the controversial role of SERT gene testing in predicting SSRI response with Dr. Chris Aiken. Can genetic testing really tell us which patients will respond to antidepressants, or are we putting too much faith in pharmacogenetic promises that lack solid evidence?
Faculty: Chris Aiken, M.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 0.75 CME: The Role of Genetic Testing in Psychiatry
SERT Gene and SSRI Response: Is It Clinically Useful?

In this episode, we explore a critical drug interaction: SSRIs combined with anticoagulants increase major bleeding risk by 35-47%. Should age and sex change our prescribing decisions? We break down the evidence from nearly 100,000 patients and discuss safer antidepressant alternatives for high-risk individuals.
Faculty: Paul Zarkowski, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CME: Quick Take Vol. 77
Do SSRIs Increase Major Bleeding Risk with Oral Anticoagulants?

In this episode, we explore the paradox of pharmacogenetic testing with Dr. Chris Aiken: why do these tests consistently fail in clinical trials despite showing promise in understanding drug metabolism? Could industry bias and statistical noise be masking the truth about personalized psychiatric medicine?
Faculty: Chris Aiken, M.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 0.75 CME: The Role of Genetic Testing in Psychiatry
Pharmacogenetic Panels: Do They Really Work?

In this episode, we explore how Lurasidone at lower doses (20-60 mg/day) effectively treats both depression and anxiety in bipolar I disorder. Why does the lower dose range outperform higher doses for patients with severe anxiety? Discover the surprising dose-dependent effects and metabolic advantages that make this a game-changer.
Faculty: Kristin Raj, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here.
Earn 0.75 CMEs: Quick Take Vol. 77
Is Lurasidone Effective for Bipolar Depression with Comorbid Anxiety?